The global DT-based combined vaccines market is anticipated to grow at a significant CAGR of 6.5% during the forecast period 2022-2028. The major factor which is attributing to the market growth is the rising awareness among people for vaccination against several diseases. The rise in cases of diphtheria and tetanus are constantly being seen. The major players of the market are adopting various strategies, including collaborations and mergers in order to remain competitive in the market and to develop new vaccines and medications. For Instance, in March 2021, Stablepharma Ltd. announced a collaboration with European vaccine manufacturer BB-NCIPD to develop a thermally stable version of the tetanus-diphtheria (Td) vaccine using the patented StablevaX formulation and device. According to World Health Organization (WHO), BB-NCIPD Ltd. is a supplier of around 9% of the global demand for Td vaccines in 2019. The global demand for the vaccine is estimated to be around 270 million doses and continues to grow mainly driven by WHO’s recommendation in 2015 of moving from Tetanus alone to the Td combination vaccine. WHO projects the demand to grow to 410 million doses by 2030.
Browse the full report description “Global DT-Based Combined Vaccines Market Size, Share, and Trends Analysis Report by Type (DTaP and DTwP) and by Application (Paediatric, Adults, Elderly, and Pregnancy) Forecast 2022-2028” at https://www.omrglobal.com/industry-reports/dt-based-combined-vaccines-market
Similarly, the Pharmaniaga Bhd had signed Memoranda of Understanding (MoU) with two biotechnology companies based in Thailand in February 2022, for vaccine, bioequivalence solutions as well as pharmaceutical products development.
Moreover, Dynavax Technologies Corp. and Serum Institute of India (SIIPL) had collaborated to address the shortcomings of the currently marketed acellular pertussis vaccines. Under the collaboration, Dynavax has exclusive worldwide rights to commercialize the vaccine, except that SII has exclusive rights to distribute in India and to fulfil WHO/UNICEF tender contracts. The parties are responsible for clinical development costs in their respective territories. In February 2021, both the companies had jointly announced that the first participant has been dosed in Phase 1 clinical trial evaluating tetanus, diphtheria, and acellular pertussis (Tdap) booster vaccine candidate adjuvanted with CpG 1018.
Market Coverage
Segment Covered-
Regions Covered-
Competitive Landscape - including, Pfizer, Inc., Sanofi S.A., Novartis International AG, Bharat Biotech Ltd., GlaxoSmithKline PLC and others
Key questions addressed by the report
o Deviation from the pre-COVID-19 forecast
o Most affected region and segment
Global DT-Based Combined Vaccines Market Report Segment
By Type
By Application
Global DT-Based Combined Vaccines Market Report Segment by Region
North America
Europe
Asia-Pacific
Rest of the World
To learn more about this report request a free sample copy @ https://www.omrglobal.com/request-sample/dt-based-combined-vaccines-market